(19)
(11) EP 1 135 534 A1

(12)

(43) Date of publication:
26.09.2001 Bulletin 2001/39

(21) Application number: 99973308.2

(22) Date of filing: 30.11.1999
(51) International Patent Classification (IPC)7C12Q 1/68, A61P 43/00, A61K 31/00
(86) International application number:
PCT/GB9903/973
(87) International publication number:
WO 0034/515 (15.06.2000 Gazette 2000/24)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 05.12.1998 GB 9826747

(71) Applicant: AstraZeneca UK Limited
London W1Y 6LN (GB)

(72) Inventors:
  • ANAND, Rakesh
    Cheshire SK10 4TG (GB)
  • MORTEN, John, Edward, Norris
    Cheshire SK10 4TG (GB)
  • SMITH, John, Craig
    Cheshire SK10 4TG (GB)

(74) Representative: Gainey, Laurence David Scott et al
AstraZeneca,Global Intellectual Property,P.O Box272,MeresideAlderley Park
Macclesfield, Cheshire SK10 4GR
Macclesfield, Cheshire SK10 4GR (GB)

   


(54) USE OF FACTOR X POLYMORPHISM IN THE DIAGNOSIS AND TREATMENT OF FACTOR X AND/OR FACTOR XA MEDIATED DISEASES